Elevated blood active ghrelin and unaltered total ghrelin and obestatin concentrations in prostate carcinoma

Urologia Internationalis

Volumn 83, Issue 4, 2009, Pages 471-475

  Malendowicz, Witold ^a   Ziolkowska, Agnieszka ^b   Szyszka, Marta ^b   Kwias, Zbigniew ^a  

^a Department of Urology and Urooncology ^*  (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Benign prostate hyperplasia; Prostate carcinoma; Serum ghrelin; Serum obestatin

Indexed keywords

GHRELIN; OBESTATIN; PROSTATE SPECIFIC ANTIGEN;

ACYLATION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

AGED; GHRELIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 72049098765     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000251190     Document Type: Article

References (41)

1. Kojima M, Hosoda H, Date Y, Nakozato M, Matsuo H, Kangawa K: Ghrelin is a growthhormone releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
2. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB: Ghrelin - a hormone with multiple functions. Front Neuroendocrinol 2004; 25: 27-68.
3. Cassoni P, Papotti M, Ghe C, et al: Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001;86: 1738-1745.
4. Jeffery PL, Herington AC, Chopin LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol 2002; 172:R7-R11.
5. Pettersson I, Muccioli G, Granata R, Deghenghi R, Ghigo E, Ohlsson C, Isgaard J: Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 2002; 175: 201-209.
6. Volante M, Allia E, Fulcheri E, Cassoni P, Ghigo E, Muccioli G, Papotti M: Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol 2003; 162: 645-654.
7. Andreis PG, Malendowicz LK, Trejter M, Neri G, Spinazzi R, Rossi GP, Nussdorfer GG: Ghrelin and growth hormone secretagogue receptor are expressed in the rat adrenal cortex: evidence that ghrelin stimulates the growth, but not the secretory activity of adrenal cells. FEBS Lett 2003; 536: 173-179.
8. Choi K, Roh SG, Hong YH, Shrestha YB, Hishikawa D, Chen C, Kojima M, Kangawa K, Sasaki S: The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 2003; 144: 754-759. (Pubitemid 36262842)
9. Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW, Whang EE: Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun 2003; 309: 464-468.
10. Mazzocchi G, Neri G, Rucinski M, Rebuffat P, Spinazzi R, Malendowicz LK, Nussdorfer GG: Ghrelin enhances the growth of cultured human adrenal zona glomerulosa cells by exerting MAPK-mediated proliferogenic and antiapoptotic effects. Peptides 2004; 25: 1269-1277.
11. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, et al: Obestatin, a peptide encoded by the ghreline gene opposes ghrelin's effects on food intake. Science 2005; 310: 996-999.
12. Gourcerol G, Tache Y: Obestatin - a ghrelinassociated peptide that does not hold its promise to suppress food intake and motility. Neurogastroenterol Motil 2007; 19: 161-165.
13. Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP: Obestatin reduces food intake and suppresses body weight gain in rodents. Biochem Biophys Res Commun 2007; 357: 264-269.
14. Vestergaard ET, Hansen TK, Gormsen LC, Jakobsen P, Moller N, Christiansen JS, Jorgensen JO: Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007; 292:E1829-E1836.
15. Pan W, Tu H, Kastin AJ: Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 2006; 27: 911-916.
16. Zizzari P, Longchamps R, Epelbaum J, Blues- Pajot MT: Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology 2007; 148: 1648-1653.
17. Cassoni P, Ghe C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R, Ghigo E, Papotti M, Muccioli G: Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 2004; 150: 173-184.
18. Yeh AH, Jeffery PL, Duncan RP, Herington AC, Chopin LK: Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen- activated protein kinase in prostate cancer. Clin Cancer Res 2005; 11: 8295-8303.
19. Lanfranco F, Baldi M, Cassoni P, Bosco M, Ghe C, Muccioli G: Ghrelin and prostate cancer. Vitam Horm 2008; 77: 301-324.
20. Deurenberg P, Weststrate JA, Seidell JC: Body mass index as a measure of body fatness: age and sex specific prediction formulas. Br J Nutr 1991; 65: 105-114.
21. Park WH, Oh YJ, Kim GY, Kim SE, Paik KH, Han SJ, Kim AH, Chu SH, Kwon EK, Kim SW, Jin DK: Obestatin is not elevated or correlated with insulin in children with Prader- Willi syndrome. J Clin Endocrinol Metab 2007; 92: 229-234.
22. Fontenot E, DeVente JE, Seidel ER: Obestatin and ghrelin in obese and in pregnant women. Peptides 2007; 28: 1937-1944.
23. Qi X, Li L, Yang G, Li K, Tang Y, Liou H, Boden G: Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol 2007; 66: 593-597.
24. Huda MSB, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P, Ranganath L, Pinkney J, Wilding JPH: Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond) 2008; 32: 129-135.
25. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML: Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709. (Pubitemid 32242624)
26. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240-244.
27. Tanaka M, Naruo T, Yasuhara D, Tatebe Y, Nagai N, Shiiya T, Nakazato M, Matsukura S, Nozoe S: Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology 2003; 28: 829-835.
28. Janas-Kozik M, Krupka-Matuszczyk I, Malinowska- Kolodziej I, Lewin-Kowalik J: Total ghrelin plasma level in patients with the restrictive type of anorexia nervosa. Regul Pept 2007; 140: 43-46.
29. Zamrazilova H, Hainer V, Sedlaèkova D, Papežova H, Kunešova M, Bellisle F, Hill M, Nedvidkova J: Plasma obestatin levels in normal weight, obese and anorectic women. Physiol Res 2008; 13(suppl 1):S49-S55.
30. Caminos JE, Seoane LM, Tovar SA, Casanueva FF, Dieguez C: Influence of thyroid status and growth hormone deficiency on ghrelin. Eur J Endocrinol 2002; 147: 159-163.
31. Riis AL, Hansen TK, Moller N, Weeke J, Jorgensen J: Hyperthyroidism is associated with suppressed circulating ghrelin levels. J Clin Endocrinol Metab 2003; 88: 853-857.
32. Waœko R, Komarowska H, Warenik-Szymankiewicz A, Sowiñski J: Elevated ghrelin plasma levels in patients with polycystic ovary syndrome. Horm Metab Res 2004; 36: 170-173.
33. Gimenez-Palop O, Gimenez-Perez G, Mauricio D, Berlanga E, Potau N, Vilardell C, Arroyo J, Gonzalez-Clemente JM, Caixas A: Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur J Endocrinol 2005; 153: 73-79.
34. Altinova AE, Toruner FB, Akturk M, Elbeǧ S, Yetkin I, Cakir N, Arslan M: Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm Res 2006; 65: 295-299. (Pubitemid 43876733)
35. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104: 2034-2038.
36. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, Kojima M, Kangawa K, Kohno N: Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9: 774-778.
37. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920-2926.
38. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, Oberman B, Catane R, Kaufman B, Shimon I: Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006; 106: 966-973.
39. Tacke F, Brabant G, Kruck E, Horn R, Schoffski P, Hecker H, Manns MP, Trautwein C: Ghrelin in chronic liver disease. J Hepatol 2003; 38: 447-454.
40. Guo ZF, Zheng X, Qin YW, Hu JQ, Chen SP, Zhang Z: Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 2007; 92: 1875-1880.
41. Vicennati V, Genghini S, De Iasio R, Pasqui F, Pagotto U, et al: Circulating obestatin levels and ghrelin/obestatin ratio in obese women. Eur J Endocrinol 2007; 157: 295- 301.